Find a Tender
complete
Official procurement procedure
Use of PET and MRI imaging facilities, plus [11C] radiopharmaceuticals at Invicro LLC
Medical solutions
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: University of Exeter: "Use of PET and MRI imaging facilities, plus [11C] radiopharmaceuticals at Invicro LLC". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | University of Exeter | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: University of Exeter
Market Analytics
Derived from OCDS awards & bid statistics
Published history for University of Exeter. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
31.4Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 117 active published awards; 91 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityUniversity of Exeter | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published21 Oct 2022, 10:52 BST | Last source update21 Oct 2022, 10:52 BST | Recurring procurementNot published |
ClassificationMedical solutions | ||
Delivery area | ||
OCIDocds-h6vhtk-0377ba | ||
What is being bought
PET and MRI scanning, radioligand production, and biomarker analysis
What changed
From the official release history
- Status changed to complete
21 Oct 2022, 10:52 BST - Official notice release published
21 Oct 2022, 10:52 BST - Buyer information updated
21 Oct 2022, 10:52 BST
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcancelledPublished valueNot publishedPET and MRI scanning, radioligand production, and biomarker analysis • Only UK provider of PET tracers [11C]BU90008, [11C]SA4503, and [18F]BCPP-EF, that are currently used for our studies. • Invicro is located within the Hammersmith Hospital Campus, its location accommodates research participants for image and clinical assessments without increased burden and travel for the participants. While also reducing cost and time to conduct the studies. • [11C] tracers (with short half-life of about 20 minutes) and of [18F] radiotracers (with half-life of about 120 minutes) are produced in house and the short half-life of the [11C] tracers means Invicro’s two in-house cyclotron’s must be used. Their radioligand development platform means implementation of new tracers is not available at other facilities. • Invicro has the equipment and facilities to collect arterial blood samples during the scans and analyze the quantity of the radioactive metabolites on site.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
21 Oct 2022, 10:52 BST - Award active
Not published · Not published - Contract active
Signed 13 Oct 2022, 00:00 BST · £1,883,380
Commercial outcome and competition
Awards Imanova Not published · Not published · active |
Contracts TBC £1,883,380 · signed 13 Oct 2022, 00:00 BST · active |
Bid statistics bids: 1 (lot 1) |
Buyer and organisations in this procedure
University of Exeter
Contracting authority GB-FTS-1655Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleThe research conducted by the Neurodegeneration Imaging Group requires the use of [11C] radiopharmaceutical, as well as an imaging facility that can provide PET-MR scanners with accompanying arterial line capabilities. Due to the very short half-life of the the [11C] tracers, these research studies are limited to facilities that have an in-house cyclotron. Imanova, trading as Invicro, not only has the in-house production of the [11C] tracers, which have a short half-life of approximately 20 minutes and the [18F] radiotracers with a half-life of approximately 120 minutes, they also host two cyclotrons on site. This coupled with the research facility’s location in London, where participants who are participating in the study have clinics has resulted in, for technical reasons, only Invicro being able to provide the tracers and in-house service to deliver the research outputs at present. |